Amy E. Veroff

780 total citations
23 papers, 643 citations indexed

About

Amy E. Veroff is a scholar working on Psychiatry and Mental health, Cognitive Neuroscience and Pharmacology. According to data from OpenAlex, Amy E. Veroff has authored 23 papers receiving a total of 643 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Psychiatry and Mental health, 10 papers in Cognitive Neuroscience and 4 papers in Pharmacology. Recurrent topics in Amy E. Veroff's work include Dementia and Cognitive Impairment Research (9 papers), Alzheimer's disease research and treatments (4 papers) and Cholinesterase and Neurodegenerative Diseases (4 papers). Amy E. Veroff is often cited by papers focused on Dementia and Cognitive Impairment Research (9 papers), Alzheimer's disease research and treatments (4 papers) and Cholinesterase and Neurodegenerative Diseases (4 papers). Amy E. Veroff collaborates with scholars based in United States, Switzerland and Australia. Amy E. Veroff's co-authors include Neal R. Cutler, René Spiegel, Albert Enz, Ezio Giacobini, John J. Sramek, Godfrey D. Pearlson, Ellen Grober, Richard B. Lipton, John J. Sramek and J. Raymond DePaulo and has published in prestigious journals such as Nature, American Journal of Psychiatry and Annals of the New York Academy of Sciences.

In The Last Decade

Amy E. Veroff

23 papers receiving 618 citations

Peers

Countries citing papers authored by Amy E. Veroff

Since Specialization

Citations

This map shows the geographic impact of Amy E. Veroff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy E. Veroff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy E. Veroff more than expected).

Fields of papers citing papers by Amy E. Veroff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy E. Veroff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy E. Veroff. The network helps show where Amy E. Veroff may publish in the future.

Co-authorship network of co-authors of Amy E. Veroff

This figure shows the co-authorship network connecting the top 25 collaborators of Amy E. Veroff. A scholar is included among the top collaborators of Amy E. Veroff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy E. Veroff. Amy E. Veroff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial 2022 ·The Journal of Prevention of Alzheimer s Disease ·Kathryn V. Papp, Hany Rofael, Amy E. Veroff, Michael Donohue, (unknown), Christopher Randolph, Ellen Grober, H. Robert Brashear, Gerald Novak, Karin Ernström, Rema Raman, Paul Aisen, Reisa A. Sperling, Gary Romano, David Henley	17
2	P1‐362: Longitudinal Analysis of The Free and Cued Selective Reminding Test in Pre‐Clinical and Clinical Alzheimer's Disease: Temporal Unfolding of Stages of Memory Impairment 2016 ·Alzheimer s & Dementia ·Ellen Grober, Amy E. Veroff, Richard B. Lipton	1
3	P2‐257: Verbal fluency tests: Sensitivity to disease or drug effects not affected by simplifying scoring 2012 ·Alzheimer s & Dementia ·Amy E. Veroff, Peter J. Snyder, Amy Fredrickson, Robert H. Pietrzak, Joanne Gale, Paul Maruff	1
4	Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit 2002 ·Journal of Neural Transmission ·Ezio Giacobini, René Spiegel, Albert Enz, Amy E. Veroff, Neal R. Cutler	191
5	The status of ongoing trials for mild cognitive impairment 2001 ·Expert Opinion on Investigational Drugs ·John J. Sramek, Amy E. Veroff, Neal R. Cutler	13
6	Mild Cognitive Impairment: Emerging Therapeutics 2000 ·Annals of Pharmacotherapy ·John J. Sramek, Amy E. Veroff, Neal R. Cutler	10
7	Efficacy of Xanomeline in Alzheimer Disease: Cognitive Improvement Measured Using the Computerized Neuropsychological Test Battery (CNTB) 1998 ·Alzheimer Disease & Associated Disorders ·Amy E. Veroff, N. Bodick, (unknown), John J. Sramek, (unknown)	47
8	Efficacy and Safety of BMY 21,502 in Alzheimer Disease 1996 ·Annals of Pharmacotherapy ·Rajesh C. Shrotriya, Neal R. Cutler, John J. Sramek, Amy E. Veroff, (unknown)	3
9	Assessing the neuropsychological profile of stable schizophrenic outpatients 1996 ·Journal of Neuropsychiatry ·Neal R. Cutler, Amy E. Veroff, Edyta J. Frackiewicz, (unknown), Neil M. Kurtz, (unknown)	4
10	Effects of the Cholinomimetic SDZ ENS-163 on Scopolamine-Induced Cognitive Impairment in Humans 1995 ·Journal of Clinical Psychopharmacology ·Eric P. Brass, Ronald J. Polinsky, John J. Sramek, (unknown), (unknown), Amy E. Veroff, (unknown), Neal R. Cutler	11
11	Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia. 1995 ·British Journal of Clinical Pharmacology ·N.R. Cutler, John J. Sramek, Amy E. Veroff, Gilbert Block, (unknown), Christopher Lines	41
12	Alzheimer's Disease: Optimizing Drug Development Strategies 1994 ·Neal R. Cutler, John J. Sramek, Amy E. Veroff	14
13	A Pilot Clinical Trial of the Angiotensin-Converting Enzyme Inhibitor Ceranapril in Alzheimer Disease 1993 ·Alzheimer Disease & Associated Disorders ·Abraham Sudilovsky, Neal R. Cutler, John J. Sramek, (unknown), Amy E. Veroff, (unknown), Jacqueline Markowitz, (unknown)	23
14	The Use of the Computerized Neuropsychological Test Battery (CNTB) in an Efficacy and Safety Trial of BMY 21,502 in Alzheimer's Disease 1993 ·Annals of the New York Academy of Sciences ·Neal R. Cutler, Rajesh C. Shrotriya, John J. Sramek, Amy E. Veroff, Randall D. Seifert, (unknown), (unknown)	16
15	A New Assessment Tool for Neuropsychopharmacologic Research: The Computerized Neuropsychological Test Battery 1991 ·Journal of Geriatric Psychiatry and Neurology ·Amy E. Veroff, Neal R. Cutler, John J. Sramek, (unknown), William T. Mickelson, (unknown)	37
16	CT scan and neuropsychological correlates of Alzheimer's Disease and Huntington's Disease 1982 ·Brain and Cognition ·Amy E. Veroff, Godfrey D. Pearlson, Hyo Seung Ahn	8
17	Use of CT scanning in psychiatry 1982 ·Psychosomatics ·Godfrey D. Pearlson, Amy E. Veroff, Thomas N. Wise	2
18	The neuropsychology of aging 1980 ·Psychological Research ·Amy E. Veroff	45
19	A structural determinant of hemispheric processing of pictorial material 1978 ·Brain and Language ·Amy E. Veroff	27
20	Can linguistic competence be dissociated from natural language functions? 1975 ·Nature ·Errol Baker, (unknown), Howard Gardner, Edgar Zurif, Lynn Davis, Amy E. Veroff	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact